About us - Intacare

Professor Mark Glaser

Medical Director

A professor of high energy physics at Imperial College, London. Previously Chief of Service and still holding an emeritus honorary contract to treat complicated cancer cases. At Mass General Hospital Boston (Harvard University) he studied the clinical use of Proton Beam Therapy (PBT). Professor Glaser has an exceptional knowledge of all cancers and has a particular interest in neurological and urological cancers. He has particular interest in solutions to improved clinical outcomes through clinical decision support.

Roger Miles

Director and Chief Finance Officer

Roger is a Qualified Chartered Certified Accountant and Director of his own accountancy practice – Austin, Taylor Chartered Certified Accountants – which provides a wide range of services to SME’s including across a variety of sectors and includes advice on company start-up, fund raising, acquisitions and disposals, mergers and demergers. Prior to acquiring Austin, Taylor Roger was Finance Director of several private companies owned by Lord Sainsbury and Lord Chelsea, and was Group Finance Director of Masterplug Ltd / BG Electrical Ltd (which was sold to private equity) and Bel UK Ltd a subsidiary of Fromageries Bel. Roger was also an associate of Beer & Partners which was the largest source for Business Angel Capital in the UK.

Dr Vincent Khoo

Senior Scientific Advisor

Specialising in urological cancers, Vincent currently holds a full time substantive post at The Royal Marsden NHS Foundation Trust. Vincent is also Honorary Consultant at St George’s Hospital, London. He is also Honorary Senior Lecturer at the Institute of Cancer Research, University of London, UK. Internationally, Vincent is an Adjunct Professor at the Department of Medical Imaging and Radiation Sciences, Monash University, and Honorary Associate Professor at the Department of Medicine, Melbourne University. Vincent has a special focus on phase I to IV studies clinical trials through his Clinical Trials Unit. Vincent has a special interest in AI-supported outcomes assessment and predictive modelling for trial optimisation.

Ken Anderson

Chairman

Ken Anderson is a corporate finance and health care executive with a wealth of experience in both financing and operating world class medical facilities and is seen as a global expert within the industry. Ken was the first Commercial Director General at the Department of Health and a member of the department’s management board. In this role, he was responsible for the introduction of non-NHS provided clinical services, negotiating the PPRS the UK’s drug purchasing agreement worth £12 billion annually and the rationalisation of the £14 billion NHS supply chain including the £20 billion outsourcing of NHS Logistics. Ken currently holds the position of Senior Advisor at Greenhill & Co. Ken joined Greenhill in 2014 after over 7 years with UBS in London. At UBS, Ken was first a Managing Director and then a Vice Chairman. Ken works with clients in a variety of industries with an emphasis on services, healthcare and energy. Prior to joining the Department of Health Ken was CEO for a division of HCA responsible for owning and operating a system of 24 hospitals in the US. Ken is Adjunct Professor of Finance at the Imperial College Business School.

Brendan Harris

Intacare Head of Research and Evidence

Brendan is a qualified, HCPC-registered senior therapeutic radiographer with 20 years of clinical experience in oncology services. Brendan holds a bachelor’s degree in Radiotherapy and Oncology, a Foundation Prince 2 – Project Management and a diploma in First Line Management through the Institute of Leadership and Management. Brendan has worked in many of the leading NHS teaching hospitals in London in public and private services. Brendan supports the technical team in developing algorithms based on sound clinical evidence and research.

Sam Dayani

Director

Samuel Dayani is a partner at the Joseph Samuel Group, where he is responsible for managing the Group’s investments and business development in the Real Estate, Medtech, Energy & Renewables, Fashion and Technology & Telecoms sectors. Samuel was responsible for purchasing CentralNic in 2003 and managing the restructuring of the business, building the management team and delivering an institutional grade business for its listing in 2013. Previously Samuel was the Chief Operating Oﬃcer and later Managing Director of ViaVision Ltd, an interactive TV company on Sky, when it was sold to Yoomedia plc in 2004. Samuel graduated from Queen Mary College, University of London with a Bachelor of Science in Business and Biology in 2000.

Our Services

Our world-leading expertise